-
7m 20sPart 2 | Session 2 VOLT AF IDE
-
5m 53sPart 2 | Session 3 VERITAS Study: Next-Generation LAA Closure with Amulet 360
-
3m 48sPart 2 | Session 4 STYLE AF Update: Venous Vascular Closure in AF Patients
-
4m 50sPart 2 | Session 5 Balloon-in-Basket PFA without Propofol
-
5m 58sPart 2 | Session 6 ADVENT LTO: Long-Term PFA Outcomes and AF Progression
-
4m 16sPart 3 | Session 1 4 Trials That Will Change My Practice with Dr Luigi Di Biase
-
5m 18sPart 3 | Session 2 AF & EP in 2026: Five Things That Will Change Daily Practice
-
10m 44sPart 1 | Session 1 Complication Prevention in Complex AF and VT Procedures
-
12m 35sPart 1 | Session 2 Will PFA Redefine AF Ablation Strategies in 2026?
-
9m 39sPart 1 | Session 3 Redo AF Ablation: When to Go Beyond PVI?
Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss evolving strategies for stroke management following atrial fibrillation ablation, addressing the critical question of when anticoagulation can be safely discontinued after successful ablation.
Interview Questions:
- There's been a lot of talk about optimal anticoagulation – what's the headline? In which patients can we discontinue medication after successful ablation?
- What about in cases of silent AF recurrence, is there still a risk?
- Where does this leave us – do you think concomitant LAAC with new technologies could be the answer?
Recorded on-site at AF Symposium 2026, Boston.
Editor: Jordan Rance
Videographer: David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.
Stay up to date with our video collection covering late-breaking data from AF Symposium 2026 in Boston. Don't miss our short, accessible Expert Interviews, Discussions and Highlights of the most pertinent trials.
More from this programme
Part 1
Clinical Discussions
Part 2
Expert Interviews
Faculty Biographies
Vivek Reddy
Director of Cardiac Arrhythmia Services
Dr. Vivek Y. Reddy is a renowned cardiac electrophysiologist based in New York, currently serving as Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Director of Electrophysiology for the Mount Sinai Health System. He holds the Leona M. and Harry B. Helmsley Charitable Trust Professorship of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine at Mount Sinai. Dr. Reddy is recognized internationally for his groundbreaking clinical work in heart rhythm disorders, including atrial fibrillation, ventricular tachycardia, and the development of device-based stroke prevention strategies. Under his leadership, Mount Sinai has been the lead investigational site for numerous multinational clinical trials, including those exploring pulsed field ablation and other emerging arrhythmia technologies. In 2014, he implanted the world’s first miniature leadless pacemaker in the United States at The Mount Sinai Hospital, marking a major advance in pacing…
Comments